Shares of FibroGen, Inc. (NASDAQ:FGEN – Get Rating) have been assigned an average rating of “Hold” from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $21.83.
Several research firms have recently weighed in on FGEN. StockNews.com began coverage on FibroGen in a report on Thursday, March 31st. They issued a “hold” rating for the company. Zacks Investment Research raised FibroGen from a “strong sell” rating to a “hold” rating in a report on Thursday, March 3rd. Finally, The Goldman Sachs Group dropped their price objective on shares of FibroGen from $10.00 to $9.00 and set a “sell” rating on the stock in a research note on Tuesday, March 1st.
A number of institutional investors and hedge funds have recently modified their holdings of FGEN. Point72 Asset Management L.P. grew its position in FibroGen by 235.9% during the fourth quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company’s stock worth $52,630,000 after buying an additional 2,621,494 shares during the period. Soleus Capital Management L.P. acquired a new position in FibroGen during the fourth quarter worth about $21,862,000. Two Sigma Investments LP grew its position in FibroGen by 430.5% during the third quarter. Two Sigma Investments LP now owns 1,335,805 shares of the biopharmaceutical company’s stock worth $13,652,000 after buying an additional 1,084,016 shares during the period. First Trust Advisors LP grew its position in FibroGen by 24.8% during the fourth quarter. First Trust Advisors LP now owns 5,317,613 shares of the biopharmaceutical company’s stock worth $74,978,000 after buying an additional 1,055,536 shares during the period. Finally, Millennium Management LLC grew its position in FibroGen by 1,326.6% during the third quarter. Millennium Management LLC now owns 717,307 shares of the biopharmaceutical company’s stock worth $7,331,000 after buying an additional 667,027 shares during the period. Institutional investors own 75.75% of the company’s stock.
FibroGen (NASDAQ:FGEN – Get Rating) last posted its quarterly earnings data on Monday, February 28th. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.77). The firm had revenue of $16.54 million during the quarter, compared to analyst estimates of $47.65 million. FibroGen had a negative net margin of 123.25% and a negative return on equity of 93.23%. FibroGen’s revenue was down 74.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.64) earnings per share. On average, research analysts expect that FibroGen will post -3.17 EPS for the current year.
About FibroGen (Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.